HomeCompareFIV vs JNJ

FIV vs JNJ: Dividend Comparison 2026

FIV yields 15.61% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FIV wins by $35.6K in total portfolio value
10 years
FIV
FIV
● Live price
15.61%
Share price
$9.73
Annual div
$1.52
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$55.6K
Annual income
$4,085.89
Full FIV calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — FIV vs JNJ

📍 FIV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFIVJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FIV + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FIV pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FIV
Annual income on $10K today (after 15% tax)
$1,326.89/yr
After 10yr DRIP, annual income (after tax)
$3,473.01/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, FIV beats the other by $2,769.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FIV + JNJ for your $10,000?

FIV: 50%JNJ: 50%
100% JNJ50/50100% FIV
Portfolio after 10yr
$37.8K
Annual income
$2,456.83/yr
Blended yield
6.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FIV
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FIV buys
0
JNJ buys
0
No recent congressional trades found for FIV or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFIVJNJ
Forward yield15.61%3.36%
Annual dividend / share$1.52$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$55.6K$20.0K
Annual income after 10y$4,085.89$827.78
Total dividends collected$27.5K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FIV vs JNJ ($10,000, DRIP)

YearFIV PortfolioFIV Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,261$1,561.05$10,676$355.77+$1.6KFIV
2$14,908$1,788.79$11,407$389.39+$3.5KFIV
3$17,984$2,032.69$12,198$426.53+$5.8KFIV
4$21,535$2,291.71$13,056$467.62+$8.5KFIV
5$25,607$2,564.64$13,987$513.12+$11.6KFIV
6$30,250$2,850.08$14,998$563.56+$15.3KFIV
7$35,514$3,146.55$16,098$619.52+$19.4KFIV
8$41,452$3,452.44$17,295$681.69+$24.2KFIV
9$48,120$3,766.10$18,599$750.82+$29.5KFIV
10$55,574$4,085.89$20,022$827.78+$35.6KFIV

FIV vs JNJ: Complete Analysis 2026

FIVStock

First Trust Senior Floating Rate 2022 Target Term Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objectives are to seek a high level of current income and to return $9.85 per common share of beneficial interest of the Fund (the original net asset value) per common share before deducting offering costs of $0.02 per common share to holders of common shares on or about February 1, 2022. The Fund focuses on investing approximately 80% of its Managed Assets in a portfolio of senior secured floating-rate loans (senior loans) of any maturity. Trust Advisors L.P. is the investment advisor of the Fund.

Full FIV Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this FIV vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FIV vs SCHDFIV vs JEPIFIV vs OFIV vs KOFIV vs MAINFIV vs ABBVFIV vs MRKFIV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.